Lupin receives FDA nod for generic Lotemax
Loteprednol Etabonate Ophthalmic Suspension, 0.5%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
The Food and Drug Administration has approved Lupin’s Loteprednol Etabonate Ophthalmic Suspension, 0.5%, which is a generic of Bausch & Lomb’s Lotemax.
Loteprednol Etabonate Ophthalmic Suspension, 0.5%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
[Read more: Lupin receives FDA OK for generic Banzel]
The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.5% had a market value of roughly $59 million, per IQVIA February 2024 data.
[Read more: Lupin receives FDA nod for 3 generics]